PharmAla Advances MDMA Trial for Military PTSD Treatment

An announcement from PharmAla Biotech Holdings, Inc. ( (TSE:MDMA) ) is now available.

PharmAla Biotech Holdings Inc. has announced the progression of its contract with the University of Texas Health Science Center at San Antonio, funded by the Defense Appropriations Act. This contract involves the development of a new 20mg clinical drug product dose of LaNeo™ MDMA, which will be used in a trial to treat PTSD in active-duty military personnel. The trial, part of the STRONG STAR Consortium, aims to explore MDMA-Assisted Therapy’s effects on this novel patient population. This collaboration highlights PharmAla’s commitment to supporting military psychological health research and could significantly impact treatment options for military personnel.

More about PharmAla Biotech Holdings, Inc.

PharmAla Biotech Holdings Inc. is a biotechnology company dedicated to the research, development, and manufacturing of MDXX class molecules, including MDMA. The company focuses on alleviating the global shortage of clinical-grade MDMA for trials and commercial sales in select regions, as well as developing novel drugs in the same class. PharmAla is unique in providing clinical-grade MDMA for patient treatments outside of clinical trials.

YTD Price Performance: -31.48%

Average Trading Volume: 265,679

Technical Sentiment Consensus Rating: Sell

Learn more about MDMA stock on TipRanks’ Stock Analysis page.